Hwang Jong-Moon, Lee Byung-Joo, Oh Terry H, Park Donghwi, Kim Chul-Hyun
Department of Rehabilitation Medicine, Kyungpook National University Hospital.
Department of Rehabilitation Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.
Medicine (Baltimore). 2019 Jan;98(1):e13913. doi: 10.1097/MD.0000000000013913.
To evaluate the association between opioid use and treatment outcome (symptom severity, quality of life [QOL]) after a brief interdisciplinary fibromyalgia treatment program (FTP).
Subjects (n = 971) with fibromyalgia participated in the FTP. They filled out the Fibromyalgia Impact Questionnaire (FIQ) and the Short Form-36 Health Status Questionnaire (SF-36) at baseline and 6 to 12 months after the FTP. Post-treatment changes in FIQ and SF-36 scores were compared after stratifying the participants into opioid user and non-opioid user groups.
A total of 236 patients (24.3%) were opioid users. Compared with non-opioid users, the opioid users had worse symptom severity measured using FIQ total score (p < .001) and all subscales at baseline and post treatment, as well as worse QOL measured using all SF-36 subscales and physical and mental components. Comparison of least-square means of mean change of QOL between opioid users and non-opioid users after analysis of covariance adjusted patient characteristics and baseline scores showed that the FIQ subscale scores of physical impairment (p < .05), job ability (p < .05), and fatigue (p < .05) were significantly less improved in the opioid users compared with the non-opioid users. Moreover, the SF-36 subscale score of general health perception (p < .05) was significantly less improved in the opioid users compared with non-opioid users. However, post-treatment changes in mean scores for QOL subscale generally did not significantly differ in both groups.
Opioid use did not affect response to the FTP, as measured using the FIQ total score or SF-36 physical and mental component summary scores. Furthermore, the opioid user group showed less improvement in the FIQ subscale scores of physical impairment, job ability, and fatigue and in the SF-36 subscale scores of general health perception.
评估在一个简短的跨学科纤维肌痛治疗项目(FTP)后,阿片类药物使用与治疗结果(症状严重程度、生活质量[QOL])之间的关联。
971名纤维肌痛患者参与了FTP。他们在基线时以及FTP后6至12个月填写了纤维肌痛影响问卷(FIQ)和简短健康调查简表(SF-36)。在将参与者分为阿片类药物使用者组和非阿片类药物使用者组后,比较了FIQ和SF-36分数的治疗后变化。
共有236名患者(24.3%)为阿片类药物使用者。与非阿片类药物使用者相比,阿片类药物使用者在基线和治疗后使用FIQ总分(p<0.001)及所有子量表测量的症状严重程度更差,以及使用所有SF-36子量表及身体和精神成分测量的生活质量更差。在协方差分析调整患者特征和基线分数后,比较阿片类药物使用者和非阿片类药物使用者生活质量平均变化的最小二乘均值,结果显示,与非阿片类药物使用者相比,阿片类药物使用者在身体损伤(p<0.05)、工作能力(p<0.05)和疲劳(p<0.05)的FIQ子量表分数改善明显较少。此外,与非阿片类药物使用者相比,阿片类药物使用者在一般健康感知的SF-36子量表分数改善明显较少。然而,两组生活质量子量表平均分数的治疗后变化总体上无显著差异。
使用FIQ总分或SF-36身体和精神成分汇总分数测量时,阿片类药物使用不影响对FTP的反应。此外,阿片类药物使用者组在身体损伤、工作能力和疲劳的FIQ子量表分数以及一般健康感知的SF-36子量表分数方面改善较少。